Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02377843 · ClinicalTrials.gov registry record · NA

Making Effective Human Papillomavirus (HPV) Vaccine Recommendations

A NA study, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT02377843: Completed NA study, sponsored by University of North Carolina, Chapel Hill.

NCT02377843 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02377843, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

Coverage of HPV vaccination among US teens is low, far below Healthy People 2020 goals. A central reason for low coverage is infrequent and inadequate healthcare provider recommendation of HPV vaccine. The proposed intervention aims to train clinicians to provide effective recommendations for the vaccine using participatory or efficient communication strategies. This study will evaluate the effectiveness of two communication trainings to increase HPV vaccination coverage among adolescent patients. We will compare HPV vaccination for pediatric and family medicine clinics receiving a participatory communication training, efficient communication training, or no training. Ten clinics will be randomly assigned to each study arm for a total of 30 clinics. The primary outcome of this study is to compare the change in clinics' levels of HPV vaccination initiation coverage among 11-12 year old adolescent patients from baseline to 6 month follow-up. Secondarily, we will compare the change in HPV vaccination initiation coverage in 13-17 year old adolescents.

Primary Outcome

Analysis controlling for sex. Vaccination as measured by North Carolina Immunization Registry (NCIR).

Interventions

  • BEHAVIORAL Participatory
  • BEHAVIORAL Efficient

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2015-03
Est. Completion 2016-03
Phase NA

What the finished NCT02377843 record still lists

NCT02377843 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which Participatory is the first listed.

NCT02377843 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02377843 about?

NCT02377843 is a clinical study titled "Making Effective Human Papillomavirus (HPV) Vaccine Recommendations". Coverage of HPV vaccination among US teens is low, far below Healthy People 2020 goals. A central reason for low coverage is infrequent and inadequate healthcare provider recommendation of HPV vaccine. The proposed intervention aims to train clinicians to provide effective recommendations for the va...

What is the current status of trial NCT02377843?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2015-03. Estimated completion is 2016-03.

What interventions are being tested in trial NCT02377843?

The interventions under investigation include: Participatory (BEHAVIORAL), Efficient (BEHAVIORAL).

Who is sponsoring clinical trial NCT02377843?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02377843's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02377843, the US trial registry maintained by the National Library of Medicine. NCT02377843 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.